Artiva Biotherapeutics Inc (NASDAQ:ARTV) currently has a daily average trading volume of 278.58K but it saw 289009 shares traded in last market. With a market cap of 54.58M USD, the company’s current market price of $2.24 came falling about -2.61 while comparing to the previous closing price of $2.30. In past 52 weeks, the stock remained buoying in the range of price level as high as $17.31 and as low as $1.78. In the recent trading on the day, stock has struck highest price mark of $2.15 while lowest mark touched by it was $2.27.
Taking a look at 20-day trading activity of Artiva Biotherapeutics Inc (ARTV) gives us an average price of $2.81, while its current price level is -87.06% below from 52-week high level whereas it is 25.84% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $3.81. A closer look into the stock’s movement over the week reveals that its volatility is standing at 11.78% during that period while stretching the period over a month that increases to 22.23%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 38.43 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the H.C. Wainwright which initiated the stock as “Buy” in its note to investors issued on December 30, 2024, recommending a price target of $20 for it.
Over the week, ARTV’s stock price is moving 21.74% up while it is -49.55% when we observe its performance for the past one month. Year-to-date it is -77.78% down and over the past year.
The company is expected to be releasing its next quarterly report on 2025-Mar-23, for which analysts forecasted an EPS of -0.62 while estimate for next year EPS is -2.54.
Currently, Artiva Biotherapeutics Inc’s total number of outstanding shares is 24.29M with 22.63% of that held by the insiders while 90.85% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -33.14%. Stock has a price to book (P/B) ratio of 0.29 while price to sale or P/S ratio amounts to 218.31.
